The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

The goal of the treatment of Cushing's syndrome is rapid normalization of the negative metabolic effects and biochemical abnormalities associated with the disorder. Treatment is ultimately ...

Osilodrostat, an oral cortisol synthesis inhibitor, was previously approved for treating adults with Cushing disease, a subtype of Cushing syndrome in which the hypercortisolemia is due to pituitary ...

New research has increased knowledge about how best to manage equines with Cushing’s syndrome — for which the correct veterinarty term is Pituitary Pars Intermedia Dysfunction (PPID) — one of the most ...

“The FDA approval of Signifor for Cushing’s disease brings a novel pituitary-directed therapy to patients with limited treatment options. Today's milestone reinforces Novartis’ commitment to ...

Once a patient is diagnosed with Cushing syndrome, it's important to see a specialist for further guidance and treatment, says Grossman. Treatment will depend on whether the problem is in the ...

Cushing’s syndrome survivor and public health advocate, Ms. Aisha Adamu Fari, has urged the Federal Government to prioritize research, awareness, and early ...